An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial
2010
Abstract
This economic analysis showed that a significant reduction in major CV evens with rosuvastatin led to significantly reduced costs of CV hospitalisations and procedure.